<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655066</url>
  </required_header>
  <id_info>
    <org_study_id>PANTHERA</org_study_id>
    <nct_id>NCT04655066</nct_id>
  </id_info>
  <brief_title>Evaluation of the Subjectively Perceived Pelvic Floor Function in Patients With Gynecological Tumors and Breast Cancer Under Systemic Tumor Therapy Using a Validated Questionnaire</brief_title>
  <official_title>PANTHERA-Studie &quot;Pelvic Floor Disorders in Patients Under ANtineoplastic THERApy&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Josefs-Hospital Wiesbaden GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Josefs-Hospital Wiesbaden GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The multimodal therapy of gynecological malignancies and breast cancer often leads to an&#xD;
      impairment of the pelvic floor function. This has a major impact on the quality of life of&#xD;
      cancer patients. The aim of the study is to record and analyze the potential subjective&#xD;
      impairment of the bladder, bowel and sexual function under systemic tumor therapy as well as&#xD;
      possible influencing factors by means of validated disease-specific questionnaires. to find&#xD;
      possible starting points for the prevention and treatment of the symptoms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Primary Endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>The primary endpoint and basis for the sample size calculation is the incidence of clinically relevant deteriorations in the total score of pelvic floor function.&#xD;
Bladder function, bowel function, sedimentation problems and sexual function, QoL are recorded using scores using the validated German pelvic floor questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Type of tumor (breast cancer, ovarian cancer, cervical cancer, endometrial cancer, vulvar cancer), TNM stage, body weight, height, age, type of tumor therapy, number of previous therapies (chemoline), parity, mode of delivery, nicotine abuse, medication, previous surgery.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pelvic Floor Disorders</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with gynecological tumors and breast cancer under systemic tumor therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Breastcancer under tumor therapy&#xD;
&#xD;
          -  Gynecological carcinoma under tumor therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Boris Gabriel, Prof. Dr. med.</last_name>
    <phone>+496111771500</phone>
    <email>bgabriel@joho.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bettina Blau-Schneider, Dr. med.</last_name>
    <phone>+496111770</phone>
    <email>bblauschneider@joho.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Josefs-Hospital Wiesbaden GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Floor Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

